ORIGINAL ARTICLESVaccination aginst chronic viral carriage in The Gambia
References (15)
- et al.
Hepatitis B virus infection in two Gambian villages
Lancet
(1983) Hepatitis B vaccine in the expanded programme of immunisation: the Gambian experience
Lancet
(1989)- et al.
Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides
Lancet
(1984) - et al.
Vaccine-induced escape mutant of hepatitis B virus
Lancet
(1990) - et al.
Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal
Prog Med Virol
(1981) - et al.
The pattern of childhood hepatitis B infection in two Gambian villages
J Infect Dis
(1990) - et al.
The first 2 years of the Gambia National Cancer Registry
Br J Cancer
(1990)
Cited by (106)
Antibody response to hepatitis B vaccine is independently associated with hepatitis B breakthrough infection among adults: Results from a three-year follow-up study in China
2018, VaccineCitation Excerpt :In recent years, antibody response to HepB has been further divided into four levels, including non-response (anti-HBs < 10mIU/ml), low response (10–99 mIU/ml), normal response (100–999 mIU/ml) and high response (≥1000 mIU/ml) [16,17]. Those who could not achieve normal and high response are sometimes suggested to administrate another three doses of HepB [17,18] because non-responders and low-responders have been reported to be more likely to be infected by HBV [8,9,19]. Although immune response after HepB vaccination and risk factors for HBV infection are different between children and adults, HBV breakthrough infection among adult HepB vaccinees are not well understood.
Hepatitis Vaccines and Immunoprophylaxis
2010, GI/Liver Secrets Plus: Fourth EditionHepatitis B vaccination strategies tailored to different endemicity levels: Some considerations
2010, VaccineCitation Excerpt :Percentages of people with protective antibody levels induced by a three-dose vaccination series are lower when vaccination occurs at an older age (adults over the age of 40 years: >90% protection, by age 60 years or older: 65–75% protection) [2]. Antibody levels decrease over time after a primary three-dose vaccination series as is seen in follow-up studies in infants and children [10–17]. Results of a long-term follow-up study in a low endemic country for hepatitis B disease (Italy) showed that in 36% of the children vaccinated at infancy and 11% of the persons vaccinated at an adolescent age (recruits) anti-HBs antibody titers had dropped below the level correlated with protection 10 years after a primary series of three vaccinations [17].
Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis
2020, Travel Medicine and Infectious DiseaseCitation Excerpt :The immunogenicity outcomes varied between studies. Although the majority of studies/study subgroups (n = 29) reported similar antibody responses after ID compared to IM/SC immunisation [17,90,92,94,96–99,101,103,105–108,110–112,114–121,124,126,129,130], a considerable number of studies found inferior antibody responses in the ID group compared to IM (n = 15) [91,93,95,100,102,104,109,112,113,122,123,125,127,128,131]. Nine out of ten studies on haemodialysis patients showed potential for dose-sparing with ID immunisation [92,96–98,113,114,121,124].
Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients
2023, BMC Gastroenterology